IR Calendar

American College of Rheumatology Convergence 2022

November 10 – November 14, 2022

The accepted abstract presentations and posters are listed below and can be viewed virtually from November 8-9 at ACR

ACR Convergence 2022 Oral and Poster Presentations:

Title: Long-term Use of Voclosporin in Patients with Class V Lupus Nephritis: Results from the AURORA 2 Continuation Study
Presenting author: Amit Saxena, M.D., Assistant Professor, Department of Medicine NYU Grossman School of Medicine
Date: Saturday, November 12, 2022
Time: 1:00 p.m - 3:00 p.m ET
Session: SLE-Treatment Poster I, Abstract 0355

Title: Early Reductions in Proteinuria with Voclosporin Treatment Across Lupus Nephritis Biopsy Classes: Pooled Data from the AURA-LV and AURORA 1 Trials
Presenting author: Anca Askanase, M.D., M.P.H., Professor of Medicine, Columbia University Irving Medical Center, Department of Rheumatology
Date: Saturday, November 12, 2022
Time: 1:00 p.m - 3:00 p.m ET
Session: SLE-Treatment Poster I, Abstract 0356

Title: Voclosporin Is Effective in Achieving Proteinuria Treatment Targets in Lupus Nephritis Defined by EULAR/ERA Recommendations
Presenting author: Hans-Joachim Anders, M.D., Professor of Nephrology and Head of Renal Division, University of Munich (LMU)
Date: Saturday, November 12, 2022
Time: 1:00 p.m - 3:00 p.m ET
Session: SLE-Treatment Poster I, Abstract 0357

Title: Long-term Safety and Efficacy of Voclosporin in Hispanic and Latino Patients with Lupus Nephritis
Presenting author: Ellen M. Ginzler, M.D., M.P.H., Vice Chair for Research, Department of Medicine Chief, Rheumatology Division, SUNY Downstate Health Science University
Date: Saturday, November 12, 2022
Time: 1:00 p.m - 3:00 p.m ET
Session: SLE-Treatment Poster I, Abstract 0358

Title: AUR200: An Improved BAFF/APRIL Inhibitor with Increased Potency and Safety for the Treatment of B Cell-Mediated Diseases
Presenting author: Shawn Morales, Ph.D., Aurinia Pharmaceuticals
Date: Monday, November 14, 2022
Time: 9:00 a.m - 10:00 a.m ET
Session: Abstracts: B Cell Biology and Targets in Autoimmune and Inflammatory Disease, Abstract 1629

Title: Voclosporin for Lupus Nephritis: Assessment of Long-Term Safety and Efficacy Including Renal Outcome over Three Years of Treatment in the Phase 3 AURORA 1 and AURORA 2 Studies
Presenting author: Cristina Arriens, M.D., Clinical Assistant Member, Oklahoma Medical Research Foundation
Date: Monday, November 14, 2022
Time: 9:00 a.m - 10:30 a.m ET
Session: Abstracts: SLE-Treatment, Abstract 1653